Recent patents on experimental therapy for hepatitis C virus infection (1999 – 2002)

Bibliography

• ALTER HJ: Discovery of the non-A, non-B hepatitis virus: the end of the beginning or the beginning of the end. Transfus. Med. Rev (1989) 3(2):77–81.
   Google Scholar
• KUO G, CHOO QL, ALTER HJ et al.: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 244(4902):362–364.
   PubMed Web of Science ®Google Scholar
• ALBERTI A, BENVEGNU L: Management of hepatitis C. Hepatol. (2003) 38\(Supp1.1):S104–S118.
   Google Scholar
• WALKER MA: Hepatitis C virus: an overview of current approaches and progress. Drug Discov. Today(1999) 4(11):518–529.
   PubMedGoogle Scholar
• GIANNINI C, BRECHOT C: Hepatitis C virus biology. Cell Death Differ. (2003) 10\(Supp1.1):S27–S38.
   Google Scholar
• NAOUMOV NV, CHOKSHI S, METIVIER E, MAERTENS G, JOHNSON PJ, WILLIAMS R: Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. Hepatol. (1997) 27(2):331–336.
   Google Scholar
• SAITO I, MIYAMURA T, OHBAYASHI A et al.: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Nati Acad. Sci. USA (1990) 87(17):6547–6549.
   Google Scholar
• CASELMANN WH, ALT M: Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. Hepatol. (1996) 24(2):61–66.
   Google Scholar
• TSAI JF, JENG JE, HO MS et al.: Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br.j Cancer (1997) 76(7):968–974.
   PubMed Web of Science ®Google Scholar
• SERFATY L, AUMAITRE H, CHAZOUILLERES O et al.: Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 27(5):1435–1440.
   PubMed Web of Science ®Google Scholar
• ALTER MJ, MAST EE, MOYER LA, MARGOLIS HS: Hepatitis C. Infect. Dis. Clin. North Am. (1998) 12(1):13–26.
   PubMed Web of Science ®Google Scholar
• NISHIOKA K: Epidemiological studies on hepatitis C virus infection: detection, prevalence, exposure and prevention. Intervirology (1994) 37(2):58–67.
   Google Scholar
• ZEUZEM S, TEUBER G, LEE JH, RUSTER B, ROTH WK: Risk factors for the transmission of hepatitis C. Hepatol. (1996) 24(2):3–10.
   Google Scholar
• HOOFNAGLE JH: Course and outcome of hepatitis C. Hepatology (2002) 36(5Supp1.1):S21–S29.
   Google Scholar
• FATTOVICH G, RIBERO ML, PANTALENA M et al.: Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. .1. Viral Hepat. (2001) 8(3):206–216.
   Google Scholar
• BRECHOT C: Hepatitis C virus: molecular biology and genetic variability. Dig. Dis. Sci. (1996) 41(12Suppl.):6S-S21.
   Google Scholar
• ROFFI L, REDAELLI A, COLLOREDO G et al: Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur. I Castroenterol Hepatol. (2001) 13(5):501–506.
   Google Scholar
• ZEIN NN: Clinical significance of hepatitis C virus genotypes. Clin. Microbiol Rev (2000) 13(2):223–235.
   PubMed Web of Science ®Google Scholar
• FARCI P, PURCELL RH: Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liver Dis. (2000) 20(1):103–126.
   Google Scholar
• MIYAKAWA Y, OKAMOTO H, MAYUMI M: Classifying hepatitis C virus genotypes. Ma Med. Today (1995) 1(1):20–25.
   Google Scholar
• BUKH J, PURCELL RH, MILLER RH: At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc. Natl. Acad. Sci. USA (1993) 90(17):8234–8238.
   Google Scholar
• HIJIKATA M, KATO N, OOTSUYAMA Y, ENAKAGAWA M, SHIMOTOHNO K: Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl Acad. Sci. USA (1991) 88(13):5547–5551.
   Google Scholar
• CHOO QL, RICHMAN KH, HAN JH et al.: Genetic organization and diversity of the hepatitis C virus. Proc. Natl Acad. Sci. USA (1991) 88(6):2451–2455.
   Google Scholar
• HOUGHTON M, WEINER A, HAN J, KUO G, CHOO QL: Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology (1991) 14(2):381–388.
   PubMed Web of Science ®Google Scholar
• DE FRANCESCO R: Molecular virology of the hepatitis C virus. .1. Hepatol. (1999) 31\(Supp1.1)47–53.
   Google Scholar
• SUZUKI R, SUZUKI T, ISHII K, MATSUURA Y, MIYAMURA T: Processing and functions of hepatitis C virus proteins. Intervirology (1999) 42(2-3):145–152.
   PubMed Web of Science ®Google Scholar
• YAN Y, LI Y, MUNSHI S et al: Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein ScL (1998) 7(4):837–847.
   Google Scholar
• KIM JL, MORGENSTERN KA, GRIFFITH JP et al.: Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure (1998) 6(1):89–100.
   Web of Science ®Google Scholar
• TAI CL, PAN WC, LIAW SH YANG UC, HWANG LH, CHEN DS: Structure-based mutational analysis of the hepatitis C virus NS3 helicase.Virol. (2001) 75(17):8289–8297.
   Google Scholar
• KANG LW, CHO HS, CHA SS et al: Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein. Acta. Crystallogr. D Biol. Crystallogr: (1998) 54\(Pt1):121–123.
   Google Scholar
• DI MARCO S, RIZZI M, VOLPARI C et al.: Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. Biol. Chem. (2000) 275(10):7152–7157.
   Google Scholar
• BARTENSCHLAGER R: The NS3/4A protease of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. Viral Hepat. (1999) 6(3):165–181.
   Google Scholar
• KIM JL, MORGENSTERN KA, LIN C et al.: Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell (1996) 87(2):343–355.
   PubMed Web of Science ®Google Scholar
• BRESSANELLI S, TOMEI L, ROUSSEL A et al.: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. ScL USA (1999) 96(23):13034–13039.
   PubMed Web of Science ®Google Scholar
• LESBURG CA, CABLE MB, FERRARI E, HONG Z, MANNARINO AF, WEBER PC: Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. (1999) 6(10)937–943.
   Google Scholar
• QIN W, YAMASHITA T, SHIROTA Y, UN Y, WET W MURAKAMI S: Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology (2001) 33(3):728–737.
   Google Scholar
• BOROWSKI P, SCHALINSKI S, SCHMITZ H: Nucleotide triphosphatase/ helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res. (2002) 55(3):397–412.
   Google Scholar
• LOCARNINI SA, BARTHOLOMEUSZ A: Advances in hepatitis C: what is coming in the next 5 years?" Castroenterol. Hepatol. (2002) 17(4):442–447.
   Google Scholar
• DI BISCEGLIE AM, MCHUTCHISON J, RICE CM: New therapeutic strategies for hepatitis C. Hepatology (2002) 35(1):224–231.
   PubMed Web of Science ®Google Scholar
• GRAKOUI A, MC COURT DW, WYCHOWSKI C, FEINSTONE SM, RICE CM: A second hepatitis C virus-encoded protease. Proc. Natl. Acad. Sci. USA (1993) 90(22):10583–10587.
   PubMedGoogle Scholar
• DARKE PL, JACOBS AR, WAXMAN L, KUO LC: Inhibition of hepatitis C virus N52/3 processing by NS4A peptides. Implications for control of viral processing. " Biol. Chem. (1999) 274(49):34511–34514.
   Google Scholar
• REYES GR: The non-structural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. I Biomed. Sci. (2002) 9(3):187–197.
   Google Scholar
• GALE MJ Jr, KORTH MJ, KATZE MG: Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin. Diagn. Virol. (1998) 10(2-3):157–162.
   Google Scholar
• GIRARD S, SHALHOUB P, LESCURE P et al.: An altered cellular response to interferon and upregulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology(2002) 295(2):272–283.
   Google Scholar
• CROTTY S, MAAG D, ARNOLD JJ et al.: The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. (2000) 6(12):1375–1379.
   PubMed Web of Science ®Google Scholar
• MAAG D, CASTRO C, HONG Z et al: Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin." Biol. Chem. (2001) 276(49):46094–46098.
   Google Scholar
• KIEFT JS, ZHOU K, GRECH A et al: Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. Nat. Struct. Biol. (2002) 9(5):370–374.
   Google Scholar
• RIJNBRAND RC, LEMON SM: Internal ribosome entry site-mediated translation in hepatitis C virus replication. Curc Top. Microbial. Immunol. (2000) 242:85–116.
   PubMed Web of Science ®Google Scholar
• HONDA M, BROWN EA, LEMON SM: Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA (1996) 2(10):955–968.
   Google Scholar
• HONDA M, PING LH, RIJNBRAND RC et al.: Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology (1996) 222(1):31–42.
   Google Scholar
• YAMADA N, TANIHARA K, TAKADA A et al.: Genetic organization and diversity of the 3' non-coding region of the hepatitis C virus genome. Virology(1996) 223(1):255–261.
   Google Scholar
• ALT M, RENZ R, HOFSCHNEIDER PH, PAUMGARTNER G, CASELMANN WH: Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology (1995) 22(3):707–717.
   PubMedGoogle Scholar
• ALT M, EISENHARDT S, SERWE M, RENZ R, ENGELS JVV, CASELMANN WH: Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Ear. I Clin. Invest. (1999) 29(10):868–876.
   PubMed Web of Science ®Google Scholar
• GALLEGO J, VARANI G: The hepatitis C virus internal ribosome-entry site: a new target for antiviral research. Biochem. Soc. Trans. (2002) 30(2):140–145.
   Google Scholar
• CHRISTIE JM, CHAPEL H, CHAPMAN RW, ROSENBERG WM: Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology (1999) 30(4):1037–1044.
   Google Scholar
• BUKH J, FORNS X, EMERSON SU, PURCELL RH: Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology(2001) 44(2-3):132–142.
   PubMed Web of Science ®Google Scholar
• BEARD MR, ABELL G, HONDA M et al.: An infectious molecular clone of a Japanese genotype lb hepatitis C virus. Hepatology (1999) 30(1):316–324.
   Google Scholar
• KOLYKHALOV AA, AGAPOV EV, BLIGHT KJ, MIHALIK K, FEINSTONE SM, RICE CM: Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 277(5325):570–574.
   PubMed Web of Science ®Google Scholar
• YANAGI M, PURCELL RH, EMERSON SU, BUKHJ: Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. USA (1997) 94(16):8738–8743.
   Google Scholar
• BARTENSCHLAGER R, LOHMANN V: Novel cell culture systems for the hepatitis C virus. Antivira/Res. (2001) 52(1):1–17.
   Google Scholar
• BARTENSCHLAGER R, LOHMANN V: Replication of the hepatitis C virus. Baillieres Best Piaci Res. Clin. Castroenterof (2000) 14(2):241–254.
   Google Scholar
• LOHMANN V, KORNER F, KOCH J, HERIAN U, THEILMANN L, BARTENSCHLAGER R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285(5424):110–113.
   PubMed Web of Science ®Google Scholar
• BRONOWICKI JP, LORIOT MA, THIERS V. GRIGNON Y, ZIGNEGO AL, BRECHOT C: Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology (1998) 28(1):211–218.
   Google Scholar
• BLINDENBACHER A, DUONG FH, HUNZIKER L et al.: Expression of hepatitis C virus proteins inhibits interferon-a signalling in the liver of transgenic mice. Gastroenterology (2003) 124(5):1465–1475.
   Google Scholar
• KAWAMURA T, FURUSAKA A, KOZIEL MJ et al.: Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology (1997) 25(4):1014–1021.
   PubMed Web of Science ®Google Scholar
• FAUSTO N: A mouse model for hepatitis C virus infection? Nat. Med. (2001) 7(8):890–891.
   Google Scholar
• DI BISCEGLIE AM, HOOFNAGLE JH: Optimal therapy of hepatitis C. Hepatology (2002) 36(5Supp1.1):S121–S127.
   Google Scholar
• MANNS MP, CORNBERG M, WEDEMEYER H: Current and future treatment of hepatitis C. Indian Castroenterol. (2001) 20\(Supp1.1)C47–051.
   Google Scholar
• MCHUTCHISON JG, PATEL K: Future therapy of hepatitis C. Hepatology (2002) 36(5 Supp1.1):S245–S252.
   Google Scholar
• SIEVERT W: Management issues in chronic viral hepatitis: hepatitis C. Castroenterol Hepatol (2002) 17(4):415–422.
   Google Scholar
• LAU JY, TAM RC, LIANG TJ, HONG Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 35(5):1002–1009.
   PubMed Web of Science ®Google Scholar
• ZHOU S, LIU R, BAROUDY BM, MALCOLM BA, REYES GR: The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology (2003) 310(2):333–342.
   PubMed Web of Science ®Google Scholar
• LIN CC, LUU K, LOURENCO D, YEH LT: Viramidine, a prodrug of ribavirin, demonstrated superior liver-targeting properties and much improved toxicity profile in cynomolgus monkey studies. Hepatology (2001) 34(Suppl.):453a. Abstract.
   Google Scholar
• YEH L, FANG JW, NGUYEN M et al.: Determination of viramidine/ribavirin in human RBC following single oral dosing of viramidine in a Phase I Study. Hepatology (2002) 36(4):345A.
   Google Scholar
• STUYVER LJ, WHITAKER T, MCBRAYER TR et al.: Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. (2003) 47(1):244–254.
   PubMed Web of Science ®Google Scholar
• BEAULIEU PL, LLINAS-BRUNET M: Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Carr. Med. Chem. (2002) 1:163–176.
   Google Scholar
• MYLES DC: Recent advances in the discovery of small molecule therapies for HCV. Carr. Opin. Drug Discov. Bevel. (2001) 4(4):411–416.
   PubMedGoogle Scholar
• NARJES F, KOCH U, STEINKUHLER C: Recent developments in the discovery of hepatitis C virus serine protease inhibitors - towards a new class of antiviral agents? Expert Opin. Investig. Drugs. (2003) 12(2):153–163.
   Web of Science ®Google Scholar
• JAIN A, KASHYAP R, DEMETRIS AJ, EGHSTESAD B, POKHARNA R, FUNG JJ: A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Banspl. (2002) 8(1):40–46.
   Google Scholar
• FIRPI RJ, NELSON DR, DAVIS GL: Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Banspl. (2003) 9(1):57–61.
   Google Scholar
• CORNBERG M, HINRICHSEN H, TEUBER G et al.: Mycophenolate mofetil in combination with recombinant interferon-a-2a in interferon-non-responder patients with chronic hepatitis C. .1. Hepatol (2002) 37(6):843–847.
   Google Scholar
• MARKLAND W, MCQUAID TJ, JAIN J, KWONG AD: Broad spectrum antiviral activity of the IMP dehydrogenase inhibitor VX- 497: a comparison with ribavirin and demonstration of antiviral additivity with a interferon. Antimicrob. Agents Chemother. (2000) 44(4):859–866.
   PubMed Web of Science ®Google Scholar
• TAN SL, PAUSE A, SHI Y, SONENBERG N: Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev Drug Discov. (2002) 1(11):867–881.
   PubMed Web of Science ®Google Scholar
• DYMOCK BW: Emerging therapies for hepatitis C virus infection. Emerging Drugs (2001) 6(1):13–42.
   PubMedGoogle Scholar
• WAXMAN L, WHITNEY M, POLLOK BA, KUO LC, DARKE PL: Host cell factor requirement for hepatitis C virus enzyme maturation. Proc. Natl. Acad. Sci. USA (2001) 98(24):13931–13935.
   PubMed Web of Science ®Google Scholar
• SCHEIBEL T, BUCHNER J: The Hsp90 complex - a super-chaperone machine as a novel drug target. Biochem. Pharmacol (1998) 56(6):675–682.
   PubMed Web of Science ®Google Scholar
• PIPER PW: The Hsp90 chaperone as a promising drug target. Curt: Opin. Investig. Drugs (2001) 2(11):1606–1610.
   Google Scholar
• MIYATA Y: [Molecular chaperone Hsp90 as a novel target for cancer chemotherapy]. Nippon Yakurigaku Zasshi (2003) 121(1):33–42. Japanese.
   Google Scholar
• JOHNSON BD, CHADLI A, FELTS SJ, BOUHOUCHE I, CATELLI MG, TOFT DO: Hsp90 chaperone activity requires the full-length protein and interaction among its multiple domains. Biol. Chem. (2000) 275(42):32499–32507.
   Web of Science ®Google Scholar
• ANDRE P, GROETTRUP M, KLENERMAN P et al.: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation and T cell responses. Proc. Natl. Acad. Sci. USA (1998) 95(22):13120–13124.
   PubMed Web of Science ®Google Scholar
• FIALAIRE P, PAYAN C, VITOUR D et al.: Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.' Infect. Dis. (1999) 180(2):574–575.
   Google Scholar
• JOHN M, FLEXMAN J, FRENCH MA: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? Aids (1998) 12(17):2289–2293.
   PubMed Web of Science ®Google Scholar
• MATSIOTA-BERNARD P, VRIONI G, ONODY C, BERNARD L, DE TRUCHIS P, PERONNE C: Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. hat. Antimicrob. Agents (2001) 17(2):155–157.
   Google Scholar
• COOPER CL, PARBHAKAR MA, ANGEL JB: Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Gin. Infect. Dis. (2002) 34(9):1259–1263.
   Google Scholar
• SAVES M, RAFFI F, CLEVENBERGH P et al.: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob. Agents Chemother. (2000) 44(12):3451–3455.
   PubMed Web of Science ®Google Scholar
• SCHANG LM: Cyclin-dependent kinases as cellular targets for antiviral drugs. Antimicrob. Chemother. (2002) 50(6):779–792.
   Google Scholar
• SCHANG LM, BANTLY A, KNOCKAERT M et al.: Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus Type 1 by targeting cellular, not viral, proteins. J. Vim/. (2002) 76(15):7874–7882.
   Google Scholar
• WANG QM, HEINZ BA: Recent advances in prevention and treatment of hepatitis C virus infections. Prog. Drug Res. (2000) 55:1–32.
   PubMedGoogle Scholar
• KEE KS, JOIS SD: Design of 13-turn basedtherapeutic agents. Carr. Rhein]. Des. (2003) 9(15):1209–1224.
   Google Scholar
• THIBEAULT D, MAURICE R, PILOTE L et al.: In vitro characterization of a purified N52/3 protease variant of hepatitis C virus. J. Biol. Chem. (2001) 276(49):46678–46684.
   Google Scholar
• SULKOWSKI MS: Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver Dis. (2003) 23(2):183–194.
   PubMed Web of Science ®Google Scholar
• INGALLINELLA P, FATTORI D, ALTAMURA S et al: Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry (2002) 41(17):5483–5492.
   Google Scholar
• LAMARRE D, BAILEY M, BOLGER G et al: The discovery of BILN-2061 - an orally bioavailable small molecule inhibitor of the HCV serine protease and a promising antiviral for the treatment of hepatits C. Hepatology (2002) 36(4):279A
   Google Scholar
• BRANCH AD: A hitchhiker's guide to antisense and non-antisense biochemical pathways. Hepatology (1996) 24(6):1517–1529.
   PubMed Web of Science ®Google Scholar
• CASELMANN WH, SERWE M, LEHMANN T et al.: Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression M vitro and in vivo. World Gastroenterol (2000) 6(5):626–629.
   Google Scholar
• LEHMANN TJ, SERWE M, CASELMANN WH et al.: Design and properties of hepatitis C virus antisense oligonucleotides for liver specific drug targeting. Nucleosides Nucleotides Nucleic Adds (2001) 20(4-7):1343–1346.
   PubMed Web of Science ®Google Scholar
• TALLET-LOPEZ B, ALDAZ-CARROLL L, CHABAS S, DAUSSE E, STAEDEL C, TOULME JJ: Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent M vitro translation. Nucleic Acids Res. (2003) 31(2):734–742.
   Google Scholar
• TESSMANN K, ERHARDT A, HAUSSINGER D et al.: Cloning and molecular characterization of human high affinity antibody fragments against hepatitis C virus NS3 helicase. .1 Virol. Methods (2002) 103(1):75–88.
   Google Scholar
• HEINTGES T, ENCKE J, ZU PUTLITZ J et al.: Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor.' Med. Virol. (2001) 65(4):671–680.
   Google Scholar
• IMANISHI T, OBIKA S: [Downregulation of a gene-expression by an antisense BNA oligonucleotide]. Nippon Yakurigaku Zasshi (2002) 120(2):85–90. Japanese.
   Google Scholar
• ZHANG H, HANECAK R, BROWN-DRIVER V et al.: Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother: (1999) 43(2):347–353.
   PubMed Web of Science ®Google Scholar
• MACEJAK DG, JENSEN K L, PAVCO PA et al.: Enhanced antiviral effect in cell culture of Type 1 interferon and ribozymes targeting HCV RNA. j Viral HepaL (2001) 8(6):400–405.
   Google Scholar
• LEE PA, BLATT LM, BLANCHARD KS et al.: Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology (2000) 32(3):640–646.
   PubMed Web of Science ®Google Scholar
• OSTENDORF T, FLOEGE J: Aptamers: a novel approach to intervention studies and development of novel therapeutic approaches. Med. Kiln. (1999) 94(4):219–223.
   Google Scholar
• JAYASENA SD: Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. (1999) 45(9):1628–1650.
   Google Scholar
• GORDON SC, BACON BR, JACOBSON IM et al: A Phase 1112-week study of ISIS-14803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C. Hepatology (2002) 36(4):362A.
   Google Scholar
• TONG M, SCHIFF E, JENSEN DM et al.: Preliminary analysis of a Phase II study of heptazyme nuclease-resistent ribozyme targeting hepatitis C virus (HCV) RNA. Hepatology (2002) 36(4):360A.
   Google Scholar
• VO NV, OH JW, LAI MM: Identification of RNA ligands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology (2003) 307(2):301–316.
   Google Scholar
• NISHIKAWA F, KAKIUCHI N, FUNAJI K, FUKUDA K, SEKIYA S, NISHIKAWA S: Inhibition of HCV N53 protease by RNA aptamers in cells. Nucleic Acids Res. (2003) 31(7):1935–1943.
   Google Scholar
• JAASKELAINEN I, URTTI A: Cell membranes as barriers for the use of antisense therapeutic agents. Mlin Rev Med. Chem. (2002) 2(4):307–318.
   Google Scholar
• AURISICCHIO L, BUJARD H, HILLEN W et al.: Regulated and prolonged expression of mIEN-a in immunocompetent mice mediated by a helper-dependent adenovirus vector. Gene Ther. (2001) 8(24):1817–1825.
   Google Scholar
• PARKS RJ, CHEN L, ANTON M, SANKAR U, RUDNICKI MA, GRAHAM FL: A helper-dependent adenovirus vector system: removal of helper virus by Cm-mediated excision of the viral packaging signal. Proc. Natl Acad. ScL USA (1996) 93(24):13565–13570.
   PubMed Web of Science ®Google Scholar
• GRACIE JA, ROBERTSON SE, MCINNES IB: Interleukin-18. I Leukoc. Biol. (2003) 73(2):213–224.
   PubMed Web of Science ®Google Scholar
• LOUIS H, VAN LAETHEM JL, WU W et al.: Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation and liver fibrosis induced by carbon tetrachloride in mice. Hepatology (1998) 28(6):1607–1615.
   PubMed Web of Science ®Google Scholar
• THOMPSON KC, TROWERN A, FOWELL A et al.: Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation In vitro. Hepatology (1998) 28(6):1518–1524.
   Google Scholar
• THOMPSON K, MALTBY J, FALLOWFIELD J, MCAULAY M, MILLWARD-SADLER H, SHERON N: Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology (1998) 28(6):1597–1606.
   PubMed Web of Science ®Google Scholar
• ZEKRY A, BISHOP GA, BOWEN DG et al.: Intrahepatic cytokine profiles associated with post-transplantation hepatitis C virus-related liver injury. Liver Transpl. (2002) 8(3):292–301.
   Google Scholar
• MCHUTCHISON JG, GIANNELLI G, NYBERG L et al.: A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. Interferon Cytokine Res. (1999) 19(11):1265–1270.
   Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Anna. Rev Immunol (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245–252.
   PubMed Web of Science ®Google Scholar
• ROMANI N, GRUNER S, BRANG D et al.: Proliferating dendritic cell progenitors in human blood. I Exp. Med. (1994) 180(1):83–93.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat. Med. (1998) 4(3):328–332.
   PubMed Web of Science ®Google Scholar
• WAN Y, BRAMSON J, CARTER R, GRAHAM F, GAULDIE J: Dendritic cells transduced with an adenoviral vector encoding a model tumour-associated antigen for tumour vaccination. Hum. Gene Ther. (1997) 8(11):1355–1363.
   PubMed Web of Science ®Google Scholar
• HOMMA S, TODA G, GONG J, KUFE D, OHNO T: Preventive antitumour activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. Gastroenterol (2001) 36(11):764–771.
   Google Scholar
• ITO A, KANTO T, KUZUSHITA N et al: Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells. Gastroenterol Hepatol (2001) 16(3):309–316.
   Google Scholar
• MATSUI M, MORIYA O, ABDEL-AZIZ N et al.: Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine (2002) 21(3-4):211–220.
   Google Scholar
• BAIN C, FATMI A, ZOULIM F et al.: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 120(2):512–524.
   PubMed Web of Science ®Google Scholar
• SAROBE P, LASARTE JJ, CASARES N et al.: Abnormal priming of CD4+ T cells by dendritic cells expressing hepatitis C virus core and El proteins. Vim]. (2002) 76(10):5062–5070.
   Google Scholar
• POYNARD T, MARCELLIN P, LEE SS et al.: Randomised trial of interferon-a-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-a-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352(9138):1426–1432.
   Google Scholar
• MCHUTCHISON JG, GORDON Sc, SCHIFF ER et al.: Interferon-a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl. Med. (1998) 339(21):1485–1492.
   Google Scholar